Type of Mesothelioma:
Nintedanib as switch maintenance treatment in malignant pleural mesothelioma (NEMO): A double-blind randomized phase II trial (EORTC-08112-LCG)
Lung Cancer 2026 March [Link] Omar Abdel-Rahman, Paul Taylor, Mary O’Brien, Jo Raskin, Claudio Dazzi, Veerle Surmont, Sabrina Zonato, Robin Young, Anne-Claire Toffart, Petra Jankowska, Adam Hassani, Sandrine Marreaud, Luc Boone, Sanjay Popat Abstract Introduction: Pleural mesothelioma (PM) is a lethal malignancy in which angiogenesis and progressive fibrosis drives disease. We evaluated angiogenesis inhibition using…
Read MoreNintedanib as switch maintenance treatment in malignant pleural mesothelioma (NEMO): A double-blind randomized phase II trial (EORTC-08112-LCG)
Lung Cancer 2026 March [Link] Omar Abdel-Rahman, Paul Taylor, Mary O’Brien, Jo Raskin, Claudio Dazzi, Veerle Surmont, Sabrina Zonato, Robin Young, Anne-Claire Toffart, Petra Jankowska, Adam Hassani, Sandrine Marreaud, Luc Boone, Sanjay Popat Abstract Introduction: Pleural mesothelioma (PM) is a lethal malignancy in which angiogenesis and progressive fibrosis drives disease. We evaluated angiogenesis inhibition using…
Read MoreArtificial Intelligence in Pleural Diseases: Current Applications and Next Steps
Thoracic Research and Practice 2026 January 30 [Link] Ferhan Karataş, Öner Dikensoy Abstract Pleural diseases pose a significant burden on healthcare systems due to diagnostic challenges and high costs. Artificial intelligence (AI) has the potential to provide faster, more accurate, and more reliable results in the diagnosis of these diseases. This review evaluates the current…
Read MoreCytoreductive surgery and HIPEC for multicystic peritoneal mesothelioma: therapeutic approach in a rare benign neoplasm
Journal of Surgical Case Reports 2026 January 8 [Link] Goran Aleksandrić, Nemanja Trifunović, Jovana Trifunović, Sara Filipović, Nebojša Mitrović Abstract Multicystic peritoneal mesothelioma (MCPM) is an uncommon tumor of mesothelial origin, characterized by multiple interconnected cystic spaces and uncertain biological behavior. Although traditionally considered benign, its tendency to recur and occasionally spread within the peritoneal…
Read MoreReal-world outcomes of first-line immunotherapy and subsequent systemic therapies in pleural mesothelioma: a multicenter study in China
Translational Lung Cancer Research 2025 December 31 [Link] Binhe Tian, Boyu Sun, Zixiang Zhou, Shuman Kuang, Jiongyuan Li, Weixuan Pan, Zhe Zhu, Xiaoyan Si, Li Zhang, Jun Liu, Juhong Shi, Fang Wu, Haitao Zhao, Hanping Wang Abstract Background: Pleural mesothelioma (PM) has a poor prognosis, and immune checkpoint inhibitors (ICIs) have reshaped first-line therapy. However,…
Read MoreMulti-omic screening for pleural mesothelioma in Asbestos-Exposed Populations: A literature review and Recommendations
Lung Cancer 2026 February [Link] Kathleen Zwijsen, Ellen Heirwegh, Eline Schillebeeckx, Elly Marcq, Adrian Covaci, Ken Op de Beeck, Jan P van Meerbeeck, Jo Raskin, Annelies Janssens, Annemiek Snoeckx, Kevin Lamote Abstract Objectives: Pleural mesothelioma (PM) is an aggressive thoracic cancer related to historical exposure to asbestos fibres. Symptoms often appear at an advanced stage,…
Read MoreThe Accuracy of Video-Assisted Thoracic Surgery Pleural Biopsy in Patients with Suspected Diffuse Pleural Mesothelioma: A Real-Life Study
Journal of Clinical Medicine 2025 December 20 [Link] Ludovica Balsamo, Enrica Migliore, Eleonora Della Beffa, Luisa Delsedime, Paolo Olivo Lausi, Daniela Di Cuonzo, Filippo Lococo, Paraskevas Lyberis, Dario Mirabelli, Mauro Giulio Papotti, Enrico Ruffini, Francesco Guerrera Abstract Background: The heritage of occupational and environmental asbestos exposure in Piedmont, Italy, has resulted in an enduring diffuse…
Read MorePrognostic Value of Fibroblast Activation Protein-Directed PET Imaging in Pleural Mesothelioma
Journal of Nuclear Medicine 2026 January 22 [Link] Lukas Kessler, Felix Schwaning, Martin Metzenmacher, Kim M Pabst, Marcel Opitz, Marcel Wiesweg, Clemens Aigner, Till Ploenes, Servet Bölükbas, Fabian Doerr, Martin Stuschke, Lale Umutlu, Michael Nader, Dirk Theegarten, Wilfried E Eberhardt, Martin Schuler, Ken Herrmann, Wolfgang P Fendler, David Kersting, Hubertus Hautzel Abstract High expression of…
Read MoreReal-world outcomes of first-line immunotherapy and subsequent systemic therapies in pleural mesothelioma: a multicenter study in China
Translational Lung Cancer Research 2025 December 31 [Link] Binhe Tian, Boyu Sun, Zixiang Zhou, Shuman Kuang, Jiongyuan Li, Weixuan Pan, Zhe Zhu, Xiaoyan Si, Li Zhang, Jun Liu, Juhong Shi, Fang Wu, Haitao Zhao, Hanping Wang Abstract Background: Pleural mesothelioma (PM) has a poor prognosis, and immune checkpoint inhibitors (ICIs) have reshaped first-line therapy. However,…
Read MoreBAP1-loss in mesothelioma: molecular mechanisms and clinical opportunities
Oncogene 2026 February [Link] Jasper H L T van Genugten, Dean A Fennell, Paul Baas Abstract Mesothelioma is an aggressive cancer that is often characterized by loss of the BRCA1-associated protein 1 (BAP1) tumor suppressor gene. This alteration typically occurs as an early clonal event in mesothelioma development, making it a promising candidate for both…
Read More
Skip to content